Compare
Caris Life Sciences, Inc. vs Guardant Health, Inc. vs Castle Biosciences Inc vs RadNet, Inc.
| Latest fiscal year | Caris Life Sciences, Inc. CAI | Guardant Health, Inc. GH | Castle Biosciences Inc CSTL | RadNet, Inc. RDNT |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $812.03M | $982.02M | $344.23M | $2.04B |
| Revenue growth (YoY) | +97.0% | +32.9% | +3.7% | +11.5% |
| Gross margin | n/a | 64.5% (computed) | 79.4% (computed) | n/a |
| Operating margin | 5.6% | -44.5% | -12.4% | 3.0% |
| Net margin | -8.4% | -42.4% | -7.0% | -0.9% |
| Net income | -$68.09M | -$416.28M | -$24.16M | -$18.65M |
| EPS (Diluted) | -$3.22 | -$3.32 | -$0.83 | -$0.25 |
| Operating cash flow | $83.16M | -$184.76M | $64.35M | $298.82M |
| Free cash flow | $66.89M | -$233.07M | $28.33M | n/a |
| Cash & equivalents | $796.27M | $378.20M | $116.73M | $767.22M |
| Total assets | $1.13B | $2.01B | $578.56M | $3.76B |
| Total liabilities | $548.36M | $2.11B | $107.68M | $2.40B |
| Shareholders' equity | $577.31M | -$99.31M | $470.87M | $1.36B |
| Return on year-end equity | -11.8% | n/a | -5.1% | -1.4% |
| Shares outstanding | 282.53M | 130.64M | 29.69M | 74.04M |
Revenue, most recent five fiscal years
| Fiscal year | Caris Life Sciences, Inc. | Guardant Health, Inc. | Castle Biosciences Inc | RadNet, Inc. |
|---|---|---|---|---|
| Latest | $812.03M Ended 2025-12-31 | $982.02M Ended 2025-12-31 | $344.23M Ended 2025-12-31 | $2.04B Ended 2025-12-31 |
| 1 year earlier | $412.26M Ended 2024-12-31 | $739.02M Ended 2024-12-31 | $332.07M Ended 2024-12-31 | $1.83B Ended 2024-12-31 |
| 2 years earlier | $306.13M Ended 2023-12-31 | $563.95M Ended 2023-12-31 | $219.79M Ended 2023-12-31 | $1.62B Ended 2023-12-31 |
| 3 years earlier | n/a | $449.54M Ended 2022-12-31 | $137.04M Ended 2022-12-31 | $1.43B Ended 2022-12-31 |
| 4 years earlier | n/a | $373.65M Ended 2021-12-31 | $94.08M Ended 2021-12-31 | $1.32B Ended 2021-12-31 |